Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced a ...

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US ...

Laboratoires Pierre Fabre Singapore is delighted to announce the access for patients to BRAFTOVI® (encorafenib) in ...

Under the terms of this agreement, the aggregated potential transaction value, including development, commercial, regulatory ...

JH2-selective TYK2 inhibitor meets primary and key secondary endpoints, with over 80% of patients achieving clear or almost ...

Farrer Park Hospital (FPH) announced the introduction of the Edge® Multi-Port Endoscopic Surgical Robot (MP1000) in Singapore ...

The commercial list moved the other way. Sixty-two products applied and 58 passed formal review. In 2025 the same stage had ...

In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, ...

Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen predictive models of human immune responses.

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral ...

Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China ...

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide ...